Company / Financials
Silence Therapeutics plc Financials
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$31.6M
FY2025 · +46.1% YoY
Net Income
-$45.3M
FY2025 · +10.0% YoY
Profit Margin
-143.2%
FY2025 · net income / revenue
ROE
-33.8%
FY2025 · return on equity
Total Assets
$131.4M
FY2025
Total Debt
-
FY2025
Equity
$134.0M
FY2025
ROA
-34.5%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -22.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$31.6M+46.1% YoYNet Income HistoryProfit after all expenses and taxes-$45.3M+10.0% YoYGross Profit HistoryRevenue minus cost of goods sold$31.4M+283.9% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$11.8M-12.3% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$63.3M-3.7% YoYSG&A Expense HistorySelling, general, and administrative expenses$26.9M+4.7% YoYR&D Expense HistoryResearch and development spending$67.9M+55.9% YoYIncome Tax HistoryTotal income tax expense$845.0K+22.8% YoYEPS (Basic) HistoryBasic earnings per share-$0.33+36.5% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.33+36.5% YoY